Immunotherapy response evaluation with 18F-FDG-PET in patients with advanced stage renal cell carcinoma

Springer Science and Business Media LLC - Tập 31 - Trang 841-846 - 2011
Rozemarie Gilles1, Lioe-Fee de Geus-Oei1, Peter F. A. Mulders2, Wim J. G. Oyen1
1Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Tóm tắt

CT imaging is widely used for response evaluation of immunotherapy in patients with advanced stage renal cell carcinoma (RCC). However, this kind of treatment may not immediately be cytoreductive, although the treatment is successful. This poses new demands on imaging modalities. Positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) proved to be useful in monitoring the effect of several antitumour treatments. We investigated the potential of FDG-PET for the evaluation of response to immunotherapy. In seven patients with metastasized RCC, who were treated with either interferon-alpha (IFN-α) monotherapy or a combination of IFN-α, interleukin-2 and 5-fluorouracil, FDG-PET was performed prior and after 5 and 9 weeks of treatment. Quantitative changes of glucose metabolic rate (MRGlu) were compared with changes in tumour size on CT imaging using Response Evaluation Criteria in Solid Tumors (RECIST) and to survival and progression-free survival. No consistent changes in MRGlu were observed within different response groups. And no correlation with CT imaging, neither with survival or progression-free survival, was found. In contrast to the positive results reported on (chemo) therapy response evaluation with FDG-PET in different malignancies, this imaging modality appears not useful in response monitoring of immunotherapeutic modalities in RCC.

Tài liệu tham khảo

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. doi:10.1002/ijc.25516

Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z (1994) Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 12(1):206–212

Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2006) Positron emission tomography (PET), immuno-PET and radioimmunotherapy in renal cell carcinoma: a developing diagnostic and therapeutic relationship. BJU Int 97(5):916–922. doi:10.111/j.1464-410x.2006.06125.x

Vugrin D (1987) Systemic therapy of metastatic renal cell carcinoma. Semin Nephrol 7(2):152–162

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumours. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92(3):205–221

Delbeke D (1999) Oncological applications of FDG PET imaging: brain tumours, colorectal cancer, lymphoma and melanoma. J Nucl Med 40(4):591–603

Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J (1996) Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 23(12):1641–1674

Guay C, Lepine M, Verreault J, Benard F (2003) Prognostic value of PET using 18F-FDG in Hodgkin’s disease for posttreatment evaluation. J Nucl Med 44(8):1223–1225

Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest 124(2):608–613

de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ (2008) Chemotherapy response evaluation with FDG PET in patients with colorectal cancer. Ann Oncol 19(2):348–352. doi:10.1093/annonc/mdm470

Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, Haberkorn U, Strauss LG (2007) Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol 9(5):308–317. doi:10.1007/s11307-607-0103-6

Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumours. J Nucl Med 45(1):17–21

Chaise C, Itti E, Petegnief Y, Wirquin E, Copie-Bergman C, Farcet JP, fau-Larue MH, Meignan M, Talbot JN, Molinier-Frenkel V (2007) [F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model. Cancer Immunol Immunother 56(8):1163–1171. doi:10.1007/s00262-006-0265-0

Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL (2000) Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 41(6):999–1005

de Geus-Oei LF, Visser EP, Krabbe PF, van Hoorn BA, Koenders EB, Willemsen AT, Pruim J, Corstens FH, Oyen WJ (2006) Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med 47(6):945–949

Patlak CS, Blasberg RG, Fenstermacher JD (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 3(1):1–7

van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH (2000) Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch immunotherapy working party. Br J Cancer 82(4):772–776. doi:10.1054/bjoc.1999.0997

Lanigan D, McLean PA, Murphy DM, Donovan MG, Curran B, Leader M (1993) c-myc expression in renal carcinoma: correlation with clinical parameters. Br J Urol 72(2):143–147

Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275(29):21797–21800. doi:10.1074/bjc.c000023200

Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G (1996) Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 179(2):157–161. doi:10.1002/(SICI)1096-9896(199606)179:2<157:AID-PATH557>3.0.CO;2-S

Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B (2008) Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int 101(4):480–484. doi:10.1111/j.1464-410X.2007.07238.x

Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171(5):1806–1809. doi:10.1097/01.ju.0000120241.50061.e4

Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Hasegawa T (2006) Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging 33(6):683–691. doi:10.1007/s00259-005-0044-8

Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC (2004) Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun 25(1):11–17. doi:00006231-200401000-00003

Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S (2002) Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 9(1):15–18

Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, Bolton DM, Scott AM (2005) Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 96(4):540–546. doi:10.1111/j.1464-410X.2005.05681.x

Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD (1995) Carbon-11-acetate PET imaging in renal disease. J Nucl Med 36(9):1595–1601

Brouwers A, Verel I, van Eerd EJ, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Wylen DG, Boerman O (2004) PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm 19(2):155–163. doi:10.1089/108497804323071922

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 31

841-846

Thông tin tác giả